Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 2
1992 1
1993 2
1995 3
1996 7
1997 12
1998 26
1999 14
2000 24
2001 14
2002 9
2003 23
2004 23
2005 17
2006 14
2007 14
2008 20
2009 16
2010 12
2011 9
2012 10
2013 10
2014 9
2015 5
2016 8
2017 5
2018 2
2019 2
2020 6
2021 2
2022 1
2023 2
2024 3
2025 2
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

311 results

Results by year

Filters applied: . Clear all
Page 1
Comparison of Dorzolamide and Netarsudil on Intraocular Pressure and Ocular Perfusion in Early Glaucoma: A Randomized Controlled Trial.
Angmo D, Jain V, Warjri GB, Sharma N, Azad SV, Dada T. Angmo D, et al. J Glaucoma. 2025 Dec 1;34(12):1046-1055. doi: 10.1097/IJG.0000000000002615. Epub 2025 Jul 29. J Glaucoma. 2025. PMID: 40719703 Clinical Trial.
Congestion (40%) was the most common side effect observed in the Netarsudil group, while metallic taste (42.5%) was the most common side effect in the Dorzolamide group. The side effect profile of the 2 drugs was comparable ( P =0.65). CONCLUSION: Netarsudil causes an incr …
Congestion (40%) was the most common side effect observed in the Netarsudil group, while metallic taste (42.5%) was the most common side eff …
Randomized Multicenter Clinical Trial Comparing 0.1% Brimonidine/0.5% Timolol Versus 1% Dorzolamide/0.5% Timolol as Adjuncts to Prostaglandin Analogues: Aibeta Crossover Study.
Inatani M, Orii Y, Iwasaki K, Arimura S, Sunagawa H, Shiokawa M, Inoue K, Sakono T, Sakono T, Kuwamura R, Yoshida A, Oi J, Kuwayama Y, Kano K, Kido N, Matsuyama A, Ozaki M, Abe H, Inoue C, Nakagawa S, Musashi K, Kanamori A, Lee J, Otani S, Aoki R, Tanabe H, Nakakura S, Suzuki K, Sagara T, Saito Y, Sameshima M, Urahashi M, Watanabe-Kitamura F, Inoue T, Kagaya F, Murai Y, Mori S, Ueda K, Kurimoto T, Yamada-Nakanishi Y, Nakamura M, Yamashita T, Ishiyama S, Manabe S, Takaki K, Hayashi K, Ishida A, Tsutsui A, Manabe K, Tanito M. Inatani M, et al. Adv Ther. 2023 Sep;40(9):4074-4092. doi: 10.1007/s12325-023-02589-9. Epub 2023 Jul 15. Adv Ther. 2023. PMID: 37452961 Free PMC article. Clinical Trial.
INTRODUCTION: This multicenter, randomized, comparative, and investigator-masked crossover clinical trial sought to compare the efficacy and tolerability of fixed combinations of 0.1% brimonidine/0.5% timolol (BTFC) versus 1% dorzolamide/0.5% timolol (DTFC) as adjunctive t …
INTRODUCTION: This multicenter, randomized, comparative, and investigator-masked crossover clinical trial sought to compare the efficacy and …
Combination of Intravitreal Bevacizumab and Topical Dorzolamide versus Intravitreal Bevacizumab Alone for Diabetic Macular Edema: A Randomized Contralateral Clinical Trial.
Fazel F, Nikpour H, Pourazizi M. Fazel F, et al. Biomed Res Int. 2020 Jan 16;2020:6794391. doi: 10.1155/2020/6794391. eCollection 2020. Biomed Res Int. 2020. PMID: 32016118 Free PMC article. Clinical Trial.
PURPOSE: To evaluate the efficacy of three intravitreal bevacizumab (IVB) injections versus the same combined with 2% of topical dorzolamide in the treatment of diabetic macular edema (DME). METHODS: In this randomized double-masked clinical trial, 32 eyes of 16 treatment- …
PURPOSE: To evaluate the efficacy of three intravitreal bevacizumab (IVB) injections versus the same combined with 2% of topical dorzolam …
Comparison of the efficacy and tolerability of preservative-free and preservative-containing formulations of the dorzolamide/timolol fixed combination (COSOPT ) in patients with elevated intraocular pressure in a randomized clinical trial.
Shedden A, Adamsons IA, Getson AJ, Laurence JK, Lines CR, Hewitt DJ, Ho TW. Shedden A, et al. Graefes Arch Clin Exp Ophthalmol. 2010 Dec;248(12):1757-64. doi: 10.1007/s00417-010-1397-7. Epub 2010 May 2. Graefes Arch Clin Exp Ophthalmol. 2010. PMID: 20437244 Clinical Trial.
Mean baseline IOPs were 23.7 mmHg for both treatments at hour 0 and 21.2 mmHg for PF dorzolamide/timolol and 21.4 mmHg for PC dorzolamide/timolol at hour 2. At all study time points (trough and peak at weeks 2, 6, and 12), the difference between treatments in mean c …
Mean baseline IOPs were 23.7 mmHg for both treatments at hour 0 and 21.2 mmHg for PF dorzolamide/timolol and 21.4 mmHg for PC dorz …
A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study Group.
Boyle JE, Ghosh K, Gieser DK, Adamsons IA. Boyle JE, et al. Ophthalmology. 1998 Oct;105(10):1945-51. doi: 10.1016/s0161-6420(98)91046-6. Ophthalmology. 1998. PMID: 9787368 Clinical Trial.
INTERVENTION: After completing a washout of ocular hypotensive medications, patients were randomized to receive either the dorzolamide-timolol combination twice daily plus placebo once daily, 0.5% timolol twice daily plus placebo once daily, or 2.0% dorzolamide thre …
INTERVENTION: After completing a washout of ocular hypotensive medications, patients were randomized to receive either the dorzolamide …
The effect of combination therapy with intravitreal bevacizumab and topical timolol-dorzolamide eye drops on diabetic macular edema: a double-blind randomized controlled trial.
Fekri S, Rabiei A, Hooshmandi S, Nouri H, Abtahi SH. Fekri S, et al. Int Ophthalmol. 2024 Feb 20;44(1):101. doi: 10.1007/s10792-024-03005-z. Int Ophthalmol. 2024. PMID: 38376643 Clinical Trial.
One group received three monthly IVB injections and timolol-dorzolamide eye drops twice a day (IVB + TD group); the other group received three monthly IVB injections and artificial tear drops as placebo (IVB group). ...CONCLUSION: Our findings support the short-term effect …
One group received three monthly IVB injections and timolol-dorzolamide eye drops twice a day (IVB + TD group); the other group recei …
A controlled clinical trial of dorzolamide: a single-centre subset of a multicentre study.
Simpson AJ, Gray TB, Ballantyne C. Simpson AJ, et al. Aust N Z J Ophthalmol. 1996 Feb;24(1):39-42. doi: 10.1111/j.1442-9071.1996.tb01549.x. Aust N Z J Ophthalmol. 1996. PMID: 8743003 Clinical Trial.
IOP was measured at Hour 2 (morning peak), Hour 5 and Hour 8 (afternoon trough for dorzolamide) at baseline, Weeks 2 and 4 and Months 2, 3, 6, 9 and 12. RESULTS: Topical dorzolamide 2% solution was well tolerated and safe. Mean IOP for dorzolamide at Hour 2 w …
IOP was measured at Hour 2 (morning peak), Hour 5 and Hour 8 (afternoon trough for dorzolamide) at baseline, Weeks 2 and 4 and Months …
Effect of Adjuvant Topical Dorzolamide-Timolol vs Placebo in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.
Hsu J, Patel SN, Wolfe JD, Shah CP, Chen E, Jenkins TL, Wibbelsman TD, Obeid A, Mikhail M, Garg SJ, Ho AC, Chiang A, Spirn MJ, Vander JF. Hsu J, et al. JAMA Ophthalmol. 2020 May 1;138(5):560-567. doi: 10.1001/jamaophthalmol.2020.0724. JAMA Ophthalmol. 2020. PMID: 32239190 Free PMC article. Clinical Trial.
OBJECTIVE: To compare the short-term effect of topical dorzolamide-timolol vs placebo in eyes with neovascular AMD that have persistent exudation following intravitreal anti-VEGF injections. ...RESULTS: This trial included 52 patients. All 27 patients (100%) assigned to …
OBJECTIVE: To compare the short-term effect of topical dorzolamide-timolol vs placebo in eyes with neovascular AMD that have persiste …
Topical dorzolamide for macular holes: A randomised, double-blind, placebo-controlled trial.
Lee YM, Bahrami B, Baranage D, Sivagurunathan PD, Wong W, Bausili MM, Agrawal S, Gilhotra JS, Durkin S, Sia D, Selva D, Lake S, Casson RJ, Chan WO. Lee YM, et al. Clin Exp Ophthalmol. 2024 Nov;52(8):870-879. doi: 10.1111/ceo.14432. Epub 2024 Aug 15. Clin Exp Ophthalmol. 2024. PMID: 39145570 Clinical Trial.
Participants in both arms used topical dorzolamide 2% or saline thrice daily for 8 weeks with monthly OCT. Those with persisting FTMH underwent vitrectomy with ILM peel and gas tamponade. ...No serious adverse events were reported in either group. CONCLUSION: Topical do …
Participants in both arms used topical dorzolamide 2% or saline thrice daily for 8 weeks with monthly OCT. Those with persisting FTMH …
Comparison of the Effects of Dorzolamide/Timolol Fixed Combination versus Latanoprost on Intraocular Pressure and Ocular Perfusion Pressure in Patients with Normal-Tension Glaucoma: A Randomized, Crossover Clinical Trial.
Lee NY, Park HY, Park CK. Lee NY, et al. PLoS One. 2016 Jan 12;11(1):e0146680. doi: 10.1371/journal.pone.0146680. eCollection 2016. PLoS One. 2016. PMID: 26756747 Free PMC article. Clinical Trial.
BACKGROUD: To assess the noninferiority of a dorzolamide-timolol fixed combination (DTFC) versus latanoprost in terms of intraocular pressure (IOP) and to compare blood pressure (BP), ocular perfusion pressure (OPP) and diastolic ocular perfusion pressure (DOPP) between th …
BACKGROUD: To assess the noninferiority of a dorzolamide-timolol fixed combination (DTFC) versus latanoprost in terms of intraocular …
311 results